Showing results (121-130 of 223) with videos related to
Sort By:
Pageof 23
Oncotarget|December 18, 2013
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancerAlba Dalmases, Irene González, Silvia Menendez, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2022
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic reviewJuan C Vázquez, Antonio Piñero, Francisco J de Castro, et al.Experimental and Molecular Pathology|April 3, 2018
Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancersSuet-Feung Chin, Angela Santonja, Marta Grzelak, et al.Molecular Cancer Therapeutics|September 8, 2016
c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast CancerRaúl Rincón, Sandra Zazo, Cristina Chamizo, et al.Plos One|August 17, 2013
Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasisRodrigo Fernández-Periáñez, Irene Molina-Privado, Federico Rojo, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 13, 2022
The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overviewJuan C Vázquez, Antonio Piñero, Francisco Javier de Castro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation studyJosep Tabernero, Andres Cervantes, Fernando Rivera, et al.Cell Death Discovery|August 22, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancerSandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, et al.Cancer Medicine|April 13, 2026
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerFederico Rojo, Enriqueta Felip, Oscar Juan Vidal, et al.Investigational New Drugs|June 28, 2018
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) studyManuel Ruiz-Borrego, Begoña Jimenez, Silvia Antolín, et al.Pageof 23